Document is current
Any future updates will be listed below
-
Authors
Tesfamariam, Yonas M https://orcid.org/0000-0003-0106-7277
Christensen, Maria H https://orcid.org/0000-0003-4778-3009
Diehl, Stefan https://orcid.org/0000-0002-8058-7897
Klein, Tabea
Lingnau, Julius M
Normann, Sabine
Hagelauer, Elena
Herbert, Miriam https://orcid.org/0000-0002-8732-4766
Reimer, Sophie
Joshi, Richa P
Engels, Pujan
Pritzl, Steffen
Fontana, Pietro https://orcid.org/0000-0003-3215-3784
Zillinger, Thomas https://orcid.org/0000-0002-0866-4835
Hartmann, Gunther
Eis-Hübinger, Anna
Lam, Martin C https://orcid.org/0000-0002-4073-7379
Walgenbach, Klaus J
Meissner, Felix https://orcid.org/0000-0003-1000-7989
Wu, Hao
Schmidt, Florian I https://orcid.org/0000-0002-9979-9769
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (TRR237-369799452)
Deutsche Forschungsgemeinschaft (Emmy Noether Programme 322568668)
Deutsche Forschungsgemeinschaft (Germany's Excellence Strategy - EXC2151-390873048)
Boehringer Ingelheim Stiftung (Rise Up!)
- License Information
-
More Information
Article History
Received: 8 November 2024
Revised: 27 October 2025
Accepted: 24 November 2025
First Online: 20 January 2026
Disclosure and competing interests statement
: FIS and FM are cofounders and consultants of Odyssey Therapeutics. YMT, SN, PF, HW, and FIS are listed as inventors of a pending patent application on AIM2 nanobodies. The remaining authors declare no competing interests.
